Nymox updates progress of drug trial for prostatic hyperplasia

By Lisa Kerner

Erie, Pa., Jan. 10 - Nymox Pharmaceutical Corp. provided an update on the progress of its ongoing multi-center phase 2 trial of NX-1207, its novel drug treatment for benign prostatic hyperplasia.

NX-1207 is the company's lead drug candidate for the treatment of BPH, which afflicts approximately half of men over age 50 and close to 90% of men by age 80.

The company said the trial, nearing completion, is occurring at 35 U.S. sites.

An independent Data Monitoring Committee will shortly make its recommendations based on efficacy and safety data from the trial. Nymox expects to report on those recommendations in the near future. The company said it has provided internal safety review updates in the past which indicate there have been no significant safety issues with NX-1207 in the trial thus far.

In the earlier completed phase 1/2 trials, subjects were treated with NX-1207 and showed statistically significant overall mean symptom improvement and shrinkage in prostate size. Initial trial subjects showed an average 23.4% size reduction in the prostate after one month. No serious adverse events were reported in the earlier trials.

Nymox is a biopharmaceutical company located in Hasbrouck Heights, N.J. specializing in the research and development of therapeutics and diagnostics for the aging population.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.